This trial is active, not recruiting.

Condition retinitis pigmentosa
Treatment twice-daily dosage with 0.5% cyclosporine-a eyedrops
Sponsor Semmelweis University
Trial identifier NCT00433277, KMolnar


Using local immune suppression, the trial seeks evidence for the hypothesis that autoimmunity plays a role in the pathomechanism of retinitis pigmentosa.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Intervention model single group assignment
Masking open label

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Clinical diagnosis of retinitis pigmentosa Exclusion Criteria: - Cataract - Extremely low ERG wave amplitude (less than 8% of normal)

Trial information was received from ClinicalTrials.gov and was last updated in February 2007.
Information provided to ClinicalTrials.gov by Semmelweis University.